{
    "title": "110_hr6376",
    "content": "The Act titled \"Strengthening of FDA Integrity Act of 2008\" also includes a section on debarment. The Federal Food, Drug, and Cosmetic Act is amended to redefine the term 'drug product' and update terminology related to drug applications and devices. The Federal Food, Drug, and Cosmetic Act is amended to update terminology related to drug applications and devices by replacing terms like \"drug product application\" with \"covered application\" and \"drug subject to sections 505\" with \"drug product\". The Federal Food, Drug, and Cosmetic Act is amended to update terminology related to drug applications and devices by replacing terms like \"drug product application\" with \"covered application\" and \"drug subject to sections 505\" with \"drug product\". The amendment also defines \"covered application\" as an application for approval or licensure of a drug under section 505 of this Act or section 351 of the Public Health Service Act, respectively, or an application for clearance or approval of a device under section 510(k) or 515 of this Act, respectively. The Federal Food, Drug, and Cosmetic Act is amended to include mandatory debarment for corporations, partnerships, and associations convicted of felonies related to drug product development, approval, or regulation. The Federal Food, Drug, and Cosmetic Act is amended to include permissive debarment for offenses related to drug product development or regulation. This includes amending subclauses and redesignating clauses within the Act. The Federal Food, Drug, and Cosmetic Act is amended to include permissive debarment for offenses related to drug product development or regulation, such as bribery, fraud, and other crimes. This involves redesignating clauses and adding new provisions to the Act. The Federal Food, Drug, and Cosmetic Act is amended to include permissive debarment for offenses related to drug product development or regulation. This involves finding individuals who have demonstrated a pattern of conduct that may violate requirements under the Act or Public Health Service Act. Material participation in criminal acts can lead to debarment. The Federal Food, Drug, and Cosmetic Act allows for permissive debarment of individuals involved in criminal acts related to drug product development or regulation. Debarment may occur if a person demonstrates a pattern of conduct indicating potential violations of the Act or Public Health Service Act requirements. Amendments to section 306 outline additional considerations for debarment. The Federal Food, Drug, and Cosmetic Act is amended to include new considerations for debarment, such as the impact on public health and the availability of drug products. Effective dates for debarment are also revised to occur within one year of the violation. Additionally, an annual report to Congress on debarment proceedings is required. The Federal Food, Drug, and Cosmetic Act is amended to include new considerations for debarment proceedings, including the status of proceedings, debarments imposed, and debarments declined. Conforming amendments are made to Section 306 of the Act. The Federal Food, Drug, and Cosmetic Act is amended to include new considerations for debarment proceedings, with amendments made to various subsections regarding subparagraphs and clauses. The Federal Food, Drug, and Cosmetic Act is amended to include new considerations for debarment proceedings, with amendments made to various subsections regarding subparagraphs and clauses, such as changes in subsections (d)(3)(B)(ii), (j)(2), and (l)(2)."
}